Robert Vries
Cheif Executive Officer HUB Organoids, part of Merck
Seminars
Thursday 3rd December 2026
Beyond 3D – Choosing organoids to bring patient biology to drug development
11:40 am
- Format is not biology. Moving from 2D to 3D—or onto a chip—does not, by itself, make a model physiologically relevant or predictive. The cells, tissue origin, cellular composition, and assay context determine what biology is represented.
- Fit-for-purpose model selection starts with the decision. Cell lines, primary cells, iPSC-derived systems, and organoids each answer different questions. The right model is not necessarily the most complex model—it is the one that captures the biology needed to make the next decision with confidence.
- Patient-derived organoids bring patient biology into preclinical research. By retaining donor-specific epithelial genotype and phenotype, PDOs enable cohort-based pharmacology, biomarker discovery, resistance studies, and patient-stratification hypotheses. Their value is greatest when paired with rigorous QC and context-specific clinical correlation—not treated as a universal predictor.
Thursday 3rd December 2026
Insight Exchange – Can We Ever Reliably Predict Safety & Efficacy Before the Clinic?
12:30 pm
- Which endpoints remain hardest to predict with current models?
- How should teams balance efficacy and safety when selecting models?
- What breakthroughs are needed to improve prediction of clinical outcomes?
- Audience Q&As